CSL Behring adquire AMT-061, Hem B Gene Therapy na fase 3 de teste

CSL Behring adquire AMT-061, Hem B Gene Therapy na fase 3 de teste

CSL Behring

Imagem

Please enable the javascript to submit this form

Apoiado por bolsas educacionais da Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics e uniQure, Inc.

SSL essencial